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A b s t r a c t
The densities of diffuse, primitive, and classic β-amyloid (Aβ) deposits were studied in the temporal lobe in cognitively
normal brain, dementia with Lewy bodies (DLB), familial Alzheimer’s disease (FAD), and sporadic AD (SAD). Principal
components analysis (PCA) was used to determine whether there were distinct differences between groups or whether
Aβ pathology was more continuously distributed from group to group. Three principal components (PC) were extract-
ed from the data accounting for 56% of the total variance. Plots of cases in relation to the PC did not result in dis-
tinct groups but suggested overlap in Aβ deposition between the groups. In addition, there were linear correlations
between the densities of Aβ deposits and the distribution of the cases along the PC in specific brain regions suggest-
ing continuous variation from group to group. PC1 was associated with the degree of maturation of Aβ deposits, PC2
with differences between FAD and SAD, and PC3 with the degree of spread of Aβ pathology into the hippocampus.
Apolipoprotein E (APOE) genotype was not associated with variation in Aβ deposition between cases. PCA may be a use-
ful method of studying the pathological interface between closely related neurodegenerative disorders.
Key words: cognitively normal brain, dementia with Lewy bodies (DLB), Alzheimer’s disease (AD), β-amyloid (Aβ) deposits,
principal components analysis (PCA).
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Introduction
Studies have suggested a significant degree of
‘overlap’ or ‘interface’ between cognitively normal
brain, dementia with Lewy bodies (DLB), and Alz -
heimer’s disease (AD) [6,11,23,24]. Hence, several as -
pects of AD pathology can be observed in normal aged
brain. There is an age-related reduction in brain vol-
ume and weight, enlargement of ventricles, and loss
of synapses and dendrites in selected areas of nor-
mal brain [35]. These changes are accompanied by
many of the histological features of AD, viz., senile
plaques (SP) and neurofibrillary tangles (NFT) [1,5]. 
The major molecular constituent of the SP is β-amy-
loid (Aβ) [23] and hence, Aβ deposition in the form 
of diffuse (‘pre-amyloid’), primitive (‘neuritic’) [27,28],
and classic (‘dense-cored’) deposits is often regard-
ed as a ‘signature’ pathological feature of AD [20,30].
Nevertheless, studies have also demonstrated an over-
lap in Aβ deposition between AD and normal brain
[2,21,40]. 
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Lewy bodies presents with early frontal dementia,
cognitive fluctuations, visual hallucinations, syncope,
delusions, and rapid eye movement disorder [37]. 
The clinical and pathological features of DLB may also
overlap with AD [24,38] and this potential interface may
give rise to difficulties in clinical diagnosis. For exam-
ple, in a study of 27 clinically diagnosed cases of AD, 
six were found to have DLB by subsequent pathologi-
cal examination [43]. An essential feature of the patho-
logical diagnosis of DLB is the presence of α-synucle-
in-immunoreactive Lewy bodies (LB) in the cerebral cortex
and/or brain stem [41]. In addition, many cases of DLB
exhibit AD pathology including the presence of SP and
NFT [9,22,26,34]. In some DLB cases, the density of SP
may be sufficient for a diagnosis of AD using ‘Consor-
tium to Establish a Registry for Alzheimer’s disease’ 
(CERAD) criteria [42] and these cases are often regard-
ed as examples of ‘mixed’ or ‘multiple pathologies’ [50].
The present study compared the densities of dif-
fuse, primitive, and classic Aβ deposits in regions of
the temporal lobe in cognitively normal brain, DLB,
familial AD (FAD), and sporadic AD (SAD). The specific
objectives were: (1) to determine whether there were
distinct differences between groups or whether Aβ
pathology was more continuously distributed from
group to group and (2) to identify the most important
sources of variation in Aβ pathology between patient
groups. 
Material and methods
Cases
Cases (N = 36, details in Table I) were obtained from
the Brain Bank, Department of Neuropathology, Insti-
tute of Psychiatry, King’s College, London. Informed 
consent was given for the removal of all tissue and fol-
lowed the principles embodied in the 1964 Helsinki dec-
laration (as modified Edinburgh, 2000). Post-mortem
delay was less than 20 hours in each case. The con-
trol cases (N = 8) had no neurological or psychiatric his-
Case Group Sex Age Onset Cause of death APOE
1 Control M 64 – Pulmonary oedema 2/3
2 Control F 71 – Bronchopneumonia 3/3
3 Control M 72 – Gastrointestinal haemorrhage 3/3
4 Control M 80 – Ischaemic heart disease 3/4
5 Control F 80 – Postoperative haemorrhage 3/3
6 Control F 83 – Right femur fracture 4/4
7 Control M 84 – Peritonitis 3/3
8 Control M 85 – Ischaemic heart disease 3/3
9 DLB* M 70 65 NA 3/3
10 DLB M 72 ND Shock/Hypothermia –
11 DLB* M 68 ND Bronchopneumonia 3/3
12 DLB* M 77 74 Bronchopneumonia –
13 DLB M 69 ND Bronchopneumonia –
14 DLB M 58 51 Bronchopneumonia 3/4
15 DLB M 71 68 Myocardial infarction 3/3
16 FAD F 93 91 NA –
17 FAD F 85 76 Bronchopneumonia 3/4
18 FAD F 79 68 Bronchopneumonia –
Table I. Demographic data, cause of death, and apolipoprotein E (APOE) genotype of the cases studied
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tories and were matched as closely as possible for age
to the AD and DLB cases. The AD cases (N = 21) were
clinically assessed and all fulfilled the ‘National Insti-
tute of Neurological and Communicative Disorders and
Stroke’ and ‘Alzheimer's Disease and Related Disorders
Association’ (NINCDS/ADRDA) criteria for probable 
AD [49]. The histological diagnosis of AD was estab-
lished by the presence of widespread neocortical senile
plaques (SP) consistent with the ‘Consortium to Esta -
blish a Registry for Alzheimer’s Disease’ (CERAD) cri-
teria [42]. In addition, neurofibrillary tangles (NFT) 
were abundant in the cerebral cortex and hippocam-
pus [5]. Six of the AD cases were familial [7], with two
or more generations affected, one of which was link -
ed to a mutation of the presenilin (PSEN) gene PSEN1
[45]. The remaining FAD cases were not associated with
mutations of either amyloid precursor protein (APP) or
PSEN genes [7,19,31,45]. DLB cases (N = 7) were diag-
nosed according to the ‘Consortium on Dementia with
Lewy bodies’ (CDLB) guidelines [41]. Three of these ca-
ses had significantly less Aβ deposits than the others and
were diagnosed as ‘pure’ DLB [22,26,34]. Apo lipopro -
tein (APOE) genotype, which also influences Aβ de-
position [16,18,25], was determined for 22/36 cases
studied.
Tissue preparation 
A block of the temporal lobe, at the level of the lat-
eral geniculate body, was taken from each case and
it included the inferior temporal gyrus (ITG), the para-
hippocampal gyrus (PHG), hippocampus (HC), and den-
tate gyrus (DG). Tissue was fixed in 10% phosphate
buffered formal-saline and embedded in paraffin
wax. 7 μm coronal sections were stained with a rab-
Case Group Sex Age Onset Cause of death APOE
19 FAD F 77 72 Bronchopneumonia 3/4
20 FAD F 86 80 Bronchopneumonia 3/3
21 FAD (PSEN1) F 40 35 NA –
22 SAD F 93 91 Bronchopneumonia 3/4
23 SAD F 91 85 Bronchopneumonia –
24 SAD M 86 83 Bronchopneumonia –
25 SAD F 88 72 Bronchopneumonia –
26 SAD F 81 77 Bronchopneumonia 3/4
27 SAD F 85 80 Bronchopneumonia 3/3
28 SAD F 64 59 Bronchopneumonia 2/3
29 SAD F 80 77 Bronchopneumonia –
30 SAD F 70 64 Bronchopneumonia 3/4
31 SAD F 66 59 Bronchopneumonia –
32 SAD F 82 75 Bronchopneumonia –
33 SAD F 87 82 Myocardial infarction 3/3
34 SAD M 73 66 Bronchopneumonia –
35 SAD M 82 78 Bronchopneumonia 3/4
36 SAD F 91 83 Bronchopneumonia –
Table I. Cont.
DLB – dementia with Lewy bodies, FAD – familial Alzheimer’s disease, SAD – sporadic Alzheimer’s disease, PSEN1 – Presenilin 1, M – Male, F – Female, 
NA – data not available 
* Indicates ‘pure’ DLB with little associated AD pathology, (–) indicates not determined
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bit polyclonal antibody (Gift of Prof. B.H. Anderton, Insti-
tute of Psychiatry, King’s College London) raised to the
12-28 amino acid sequence of the Aβ protein [46]. 
The antibody was used at a dilution of 1 in 1200 and
the sections incubated at 4°C overnight. Sections were
pretreated with 98% formic acid for 6 minutes which
enhances Aβ immunoreactivity. Aβ was visualised using
the streptavidin-biotin horseradish peroxidase proce-
dure with diaminobenzidine as the chromogen. Sec-
tions were also stained with haematoxylin. The three
most common morphological subtypes of Aβ deposit
were identified in the sections using previously
defined criteria [4,21]. Hence, diffuse deposits were 
10-200 μm in diameter, irregular in shape with diffuse
boundaries, and lightly stained. Large confluent patch-
es of Aβ immunostaining, which could be a variant of
diffuse deposit, were not quantified. Primitive deposits
were 20-60 μm, well demarcated, more symmetrical
in shape, and strongly stained and may be analogous
to neuritic plaques, the predominant type of plaque
in AD [27,28]. Classic deposits were 20-100 μm, had
a distinct central ‘core’ surrounded by a ‘corona’ of dys-
trophic neurites.
Morphometric methods
In the ITG and PHG, a strip of cortex 17600 to 
25600 μm in length, and which included a sulcus 
and a gyrus, was studied using 1000 × 200 μm con-
tiguous sample fields, the short dimension of the field
being aligned with the surface of the pia mater. Hence,
the plot included laminae I, II, and most of III, the region
containing the highest densities of Aβ deposits in 
AD [3]. Between 64 and 128 contiguous sample fields
were used to sample each gyrus. A micrometer grid with
grid lines at intervals of 10 μm was used as the sam-
ple field. In the HC, the sample fields were arranged
parallel to the alveus to sample sectors CA1, CA2, and
CA3. Sampling was then continued into sector CA4
using a guideline marked on the slide and which ceased
approximately 400 μm from the DG granule cell layer.
In the DG, the lower edge of the sample field was
aligned with the top of the granule cell layer as most
Aβ deposits were located within the molecular layer.
The number of diffuse, primitive, and classic Aβ de posits
was counted manually in each field. 
Data analysis
Variations in the density and distribution of Aβ de -
posits in the temporal lobe of the 36 cases were analysed
using PCA. PCA measures the degree of similarity bet -
ween cases (the variables) based on their neuro pa -
thological characteristics [10,12,13]. Hence, each case is
defined by the density of diffuse, primitive, and classic
Aβ deposits in seven regions of the temporal lobe (viz.,
ITG, PHG, CA1, CA2, CA3, CA4, DG). Preliminary analy-
sis suggested a degree of skew and kurtosis was pre -
sent indicating a degree of non-normality in the data.
Hence, PCA was carried out on the original data and on
the data transformed to logarithms [12]. Initially, all PC
were extracted which had eigenvalues (λ) > 1 but usu-
ally in a PCA, only the first three PC account for signi -
ficant proportions of the original variance [10]. The result
of each PCA is a scatter plot of the 36 cases in relation
to the extracted PC in which the distance between cas-
es reflects their degree of similarity or dissimilarity. Hence,
if there were distinct differences in Aβ pathology bet -
ween groups, discrete clusters of cases would be pres-
ent whereas a more continuous distribution of cases 
suggests overlapping pathology or a continuum. The PC
ac count for significant proportions of variance in the data,
PC1 for the most significant source of variation and PC2
and PC3 for diminishing proportions of the remaining
variance. Hence, to identify those aspects of Aβ depo-
sition which may account for this variance, correlations
(Pearson’s ‘r’) were calculated between the ‘loadings’
(the coordinates of the case in relation to the PCs) of
each case on the PC and Aβ deposit density, age at death,
disease duration, and APOE genotype ‘score’ (the sum
of the two alleles) in each region. 
Results
Examples of diffuse, primitive, and classic Aβ de -
posits are shown in Fig. 1. Typically, diffuse deposits 
(Fig. 1A) are irregular in shape with diffuse boundaries,
and lightly stained. In contrast, primitive deposits 
(Fig. 1B) are well demarcated, more symmetrical in
shape, and strongly stained while classic deposits 
(Fig. 1C) have a distinct central ‘core’, usually incor-
porating one or more neuronal perikarya, and are sur-
rounded by a 'corona' of dystrophic neurites.
Similar PCA results were obtained using untrans-
formed and transformed data and only the results of
the analysis of the original data are reported here. 
The first three PC extracted from the data accounted
for 55.6% of the total variance (PC1 = 27.56%, PC2 =
= 15.07%, PC3 = 12.97%). The loadings of the cases in
relation to PC1 and PC2 and PC2 and PC3 are shown
in Figs. 2 and 3, respectively. No distinct groupings 
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of cases were evident on either plot suggesting con-
siderable overlap in Aβ deposition between cognitive-
ly normal cases, DLB, and AD. In the PC1/2 plot (Fig. 2),
the control and DLB cases, especially those designat-
ed as ‘pure’ DLB, exhibited high loadings on PC1 but over-
lapped extensively with the AD cases, which showed
a wide distribution over the plot. In addition, the FAD
and SAD cases did not appear to cluster in relation to
PC1 and PC2, but the FAD cases as a group had con-
sistently lower loadings on PC2 compared with the SAD
cases which appear more heterogeneous. FAD cases also
exhibited relatively low loadings on PC2 (Fig. 3) includ-
ing the case linked to a PSEN1 mutation. A proportion
of the FAD cases also exhibited high loadings on PC3.
Linear correlations between the extracted PC and
the neuropathological variables are shown in Table II.
The density of diffuse Aβ deposits in the ITG (r = 0.44,
P < 0.01) and PHG (r = 0.36, P < 0.05) were positively
correlated with PC1 while the densities of primitive
deposits in sector CA3 (r = –0.48, P < 0.01) and clas-
sic deposits in sector CA4 (r = –0.48, P < 0.01) were ne -
gatively correlated with PC1. The densities of the pri -
mitive deposits in the ITG (r = 0.55, P < 0.001) and PHG
(r = 0.59, P < 0.001) and classic deposits in the PHG
(r = 0.35, P < 0.05) were positively correlated with PC2.
The density of the diffuse deposits in sector CA1 was
positively correlated with PC3 (r = 0.36, P < 0.05) while
the densities of the primitive deposits in sectors CA1
(r = 0.72, P < 0.001) and CA2 (r = 0.58, P < 0.001) and
DG (r = 0.62, P < 0.001) were positively correlated with
PC3. The density of the classic deposits was negatively
correlated with PC3 in the ITG (r = –0.35, P < 0.05) and
A B
C
Fig. 1. The three major types of β-amyloid (Aβ)
deposit: A) diffuse (‘pre-amyloid’), B) primitive,
and C) classic (‘dense-cored’). (Aβ immunohis-
tochemistry, bar = 50 μm).
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positively correlated with PC3 in sector CA2 (r = 0.43,
P < 0.01). In addition, disease duration was positively
correlated with PC3 (r = 0.40, P < 0.05). No significant
correlations were observed between the extracted PC
and APOE score (PC1: r = 0.30, P > 0.05; PC2: r = 0.09,
P > 0.05; PC3: r = –0.05, P > 0.05).
Discussion
The objective of this study was to determine
whether cognitively normal cases, DLB, FAD, and SAD
could be easily distinguished based on the densities
of Aβ deposits in the temporal lobe. The PCA suggested:
(1) no clear separation of cases into groups and (2) lin-
ear correlations in specific regions between the den-
sities of Aβ deposits and the distribution of cases in
relation to the PCA. These data suggest continuous
change in Aβ density from group to group rather than
distinct differences between groups. 
Previous studies have reported overlaps in SP or Aβ
deposit density between cognitively normal brain and
AD. Hence, the distribution of SP was studied in 60 nor-
mal elderly cases [39] and it was concluded that it was
not possible to distinguish the early stages of AD from
normal aging on the basis of SP density alone. Simi-
larly, Bergeron et al. [17] observed SP in 60% of nor-
mal elderly cases, albeit at a lower density than in AD.
Moreover, Arrigada et al. [14] reported SP in most nor-
mal individuals older than 55 years and concluded there
may be a ‘continuum’ of pathological change between
elderly non-demented brains, early stage AD, and more
advanced AD. Aβ deposits are also present in non-
demented individuals older than 60 years but are rare
before this age [27,40]. In 14 non-demented elderly cas-
es [2], for example, Aβ deposits were present in the tem-
poral lobe in eight cases, with a considerable variation
in the density of deposits in control cases and signif-
icantly overlapping with AD. By contrast, Gibson [29]
studied 119 cases of aging and AD and found amyloid
deposits in greater numbers in AD than in normal aging.
The PCA also suggested overlap in Aβ deposition
between DLB, cognitively normal brain, and AD. DLB
exists in a multiplicity of forms including neocortical,
limbic, cerebral, and brainstem types, the neocortical
type being the most prevalent [36]. In addition, many
cases of DLB exhibit AD pathology including the pre -
sence of SP and NFT [22,26,34] with sufficient densi-
PS1 – Familial AD case linked to presenilin 1 muta-
tion. * Indicates ‘pure’ DLB cases with relatively little
AD pathology.
Fig. 2. Principal components analysis of β-amy-
loid (Aβ) deposition in the temporal lobe in cog-
nitively normal cases, dementia with Lewy bod-
ies, and Alzheimer’s disease. A plot of the cases
in relation to PC1 and PC2. 
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PS1 – Familial AD case linked to presenilin 1 muta-
 tion. * Indicate ‘pure’ DLB cases with relatively little
AD pathology.
Fig. 3. Principal components analysis of β-amy-
loid (Aβ) deposition in the temporal lobe in cog-
nitively normal cases, dementia with Lewy bod-
ies, and Alzheimer’s disease. A plot of the cases
in relation to PC2 and PC3. 
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ties of SP in some cases for a diagnosis of AD [42]. 
Aβ deposition has also been recorded in DLB [9] and
may be present at levels similar to ‘pure’ AD. There are
specific alterations in the ratio of APP isoforms com-
mon to both DLB and AD suggesting that alternate
splicing of APP mRNA may play a role in both disorders
[15] and which could explain this overlap. The presence
of LB in some cases of AD has blurred further the dis-
tinction between DLB and AD [33,47]. In a family with
a mutation of the APP gene at codon 717 (APP717), 
one individual had limbic-type DLB, two had neocor-
tical DLB, while LB were absent in the other family
members although all exhibited extrapyramidal fea-
tures [43]. To date, 53% of post-mortems of individu-
als with the APP717 mutation have revealed the pres-
ence of LB suggesting a direct link between APP and
Lewy body formation [43].
PCA identified three axes of variation in Aβ depo-
sition. Hence, PC1 is correlated with variations in den-
sity of diffuse deposits in the ITG and PHG, primitive
deposits in sector CA3, and classic deposits in sector
CA4. Hence, cases with high loadings on PC1, which
include the majority of cognitively normal, DLB, and
some AD cases, are characterized by diffuse deposits
in the ITG and PHG and low densities of primitive and
classic deposits in sectors CA3/4. Aβ deposit subtypes
could represent different stages in the maturation of
a single deposit type [4]. Hence, diffuse deposits may
represent the earliest stage of Aβ pathology and evolve
into the primitive and classic Aβ deposits as the dis-
ease progresses, the primitive (‘neuritic’) type deposit
being the most common in AD [27,28]. Hence, PC1 may
be associated with the degree of maturation of Aβ
deposits [4], the density of diffuse deposits being
greater in control and DLB and more mature deposits
in AD [27,28]. 
PC2 is correlated with variations in density of prim-
itive deposits in the ITG and PHG and classic deposits
in the PHG. Hence, cases with high loadings on PC2,
which include several SAD, some DLB, and cognitive-
ly normal cases, are characterized by high densities of
primitive and classic deposits in the ITG and PHG. By
contrast, FAD cases exhibit lower densities of primi-
tive and classic deposits in these regions. Hence, PC2
may be associated largely with variation in Aβ depo-
sition between SAD and FAD cases [7]. 
PC3 is correlated with variations in density of Aβ
deposits in sectors CA1/2 of the HC and the DG, cas-
es with low loadings on this axis, which include most
control and DLB cases, having zero or low densities of
Aβ deposits in these regions. Hence, PC3 is associat-
ed with variation in the spread of Aβ pathology into
the HC [8]. Disease duration was positively correlated
with PC3, i.e., longer duration cases were more likely
to have Aβ deposits in the HC and DG, suggesting that
this spread may occur later in the disease process. 
In consequence, control and DLB cases are more likely
not to have Aβ deposits in these regions although
deposits may be present in gyri adjacent to the HC.  
Table II. Correlations (Pearson’s ‘r’) between 
the densities of Aβ deposits in the temporal
lobe, age at death, disease duration, and apo -
lipoprotein E (APOE) score (sum of the two alle-
les) and the first three principal components (PC) 
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Region Deposit PC1 PC2 PC3
ITG Diffuse 0.44** –0.20 0.14
ITG Primitive 0.24 0.55*** 0.15
ITG Classic –0.08 0.24 –0.35*
PHG Diffuse 0.36* –0.14 –0.11
PHG Primitive 0.24 0.59*** 0.02
PHG Classic –0.03 0.35* –0.31
CA1 Diffuse 0.08 0.04 0.36*
CA1 Primitive –0.23 0.04 0.72***
CA1 Classic 0.13 0.08 0.04
CA2 Diffuse 0.09 –0.10 0.17
CA2 Primitive –0.16 –0.11 0.58***
CA2 Classic –0.15 –0.07 0.43**
CA3 Diffuse –0.15 –0.15 0.25
CA3 Primitive –0.48** –0.22 0.10
CA3 Classic –0.08 –0.24 –0.13
CA4 Diffuse –0.20 0.06 –0.22
CA4 Primitive –0.20 –0.27 –0.01
CA4 Classic –0.48** –0.10 0.29
DG Diffuse 0.04 –0.27 –0.12
DG Primitive –0.22 0 0.62***
DG Classic 0 0.07 –0.07
ITG – inferior temporal gyrus, PHG – parahippocampal gyrus, CA1-4 – sectors
of the hippocampus, DG – dentate gyrus
Significant correlations *P < 0.05, **P < 0.01, ***P < 0.001
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APOE genotype was not associated with the PC.
APOE genotype has been identified as a major risk fac-
tor in AD, individuals with AD having 2-3 times the fre-
quency of allele E4 compared with non-demented eld-
erly controls [48]. Allele E4 appears to accelerate the
development of AD pathology within the aged brain
and hence, is often associated with an earlier onset
of the disease [32]. The relationship between the dep-
osition of Aβ deposits and APOE genotype is contro-
versial but the majority of studies report increased dep-
osition in individuals expressing allele E4 [16,18,25].
Although the present data suggest some increased 
Aβ deposition in cases expressing APOE allele E4, this
source of variation is small compared with that asso-
ciated with maturation of Aβ deposits, differences bet -
ween FAD and SAD, and the spread of Aβ deposits into
the hippocampus.
In conclusion, changes in the density and distribu-
tion of Aβ deposits in the temporal lobe are unlikely to
provide a basis for a clear pathological separation of 
cognitively normal cases, DLB, and AD. Instead, Aβ dep-
osition is more continuously distributed between these
groups and cases and three axes of variation were iden-
tified: (1) the maturation of diffuse deposits, (2) va ria-
tion between FAD and SAD, and (3) the spread of Aβ
deposits into the HC. APOE genotype was not identified
as having a significant influence on Aβ deposition in this
study. PCA may be a valuable statistical me thod of study-
ing pathological changes especially in the interface bet -
ween closely related neurodegenerative disorders [6,11].
Acknowledgements
The assistance of the Brain Bank, Institute of Psy-
chiatry, King’s College London, UK, in providing tissue
sections for this study is gratefully acknowledged. 
We would like to thank Mr Andrew Chadwick and Mrs
Mavis Kibble for their excellent technical assistance.
References
1. Anderton BH. Ageing of the brain. Mech Ageing Dev 2002; 123:
811-817.
2. Armstrong RA. Beta-amyloid deposition in the medial temporal
lobe in elderly non-demented brains and in Alzheimer’s disease.
Dementia 1995; 6: 121-125.
3. Armstrong RA. β-amyloid (Aβ) deposits and blood vessels: lami-
nar distribution in the frontal cortex of patients with Alzheimer's
disease. Neurosci Res Communs 1996; 18: 19-28.
4. Armstrong RA. β-amyloid plaques: stages in life history or inde-
pendent origin? Dement Geriatr Cogn Disord 1998; 9: 227-238.
5. Armstrong RA. Plaques and tangles and the pathogenesis of
Alzheimer’s disease. Folia Neuropathol 2006; 44: 1-11.
6. Armstrong RA. The interface between Alzheimer’s disease, nor-
mal aging and related disorders. Current Aging Science 2008; 
1: 122-132.
7. Armstrong RA. Spatial patterns of β-amyloid (Aβ) deposits in famil-
ial and sporadic Alzheimer’s disease. Folia Neuropathol 2011; 49:
153-161.
8. Armstrong RA, Myers D, Smith CUM. Alzheimer’s disease: size class
frequency distribution of senile plaques: do they indicate when
a brain tissue was affected? Neurosci Lett 1991; 127: 223-226.
9. Armstrong RA, Cairns NJ, Lantos PL. β-amyloid (Aβ) deposition in
the medial temporal lobe of patients with dementia with Lewy
bodies. Neurosci Lett 1997; 227: 193-196.
10. Armstrong RA, Nochlin D, Bird TD. Neuropathological heterogeneity
in Alzheimer’s disease: A study of 80 cases using principal com-
ponents analysis. Neuropathology 2000; 20: 31-37.
11. Armstrong RA, Lantos PL, Cairns NJ. Overlap between neurode-
generative disorders. Neuropathology 2005; 25: 111-124.
12. Armstrong RA, Ellis W, Hamilton RL, Mackenzie IRA, Hedreen J, Gear-
ing M, Montine T, Vonsattel J-P, Head E, Lieberman AP, Cairns NJ.
Neuropathological heterogeneity in frontotemporal lobar degen-
eration with TDP-43 proteinopathy: a quantitative study of 94 cas-
es using principal components analysis. J Neural Transm 2010; 117:
227-239.
13. Armstrong RA, Hilton A. Statistical Analysis in Microbiology:
Statnotes. Wiley-Blackwell, Hoboken, New York 2011.
14. Arriagada PV, Marzloff K, Hyman BT. Distribution of Alzheimer-type
pathologic changes in non-demented elderly individuals match-
es the pattern in Alzheimer’s disease. Neurology 1992; 42: 1681-
1688.
15. Barrachina M, Dalfo E, Ping B, Vidal N, Freixes M, Castano E, Fer-
rer I. Amyloid-beta deposition in the cerebral cortex in DLB is accom-
panied by a relative increase in AbetaPP mRNA isoforms containing
the Kunitz protease inhibitor. Neurochem Int 2005; 46: 253-260.
16. Beffert U, Poirier J. Apolipoprotein E, plaques, tangles and cholin-
ergic dysfunction in Alzheimer’s disease. Anns NY Acad Sci 1996;
777: 166-174.
17. Bergeron C, Ranalli PJ and Miceli PN. Amyloid angiopathy in Alz -
heimer’s disease. Can J Neurol Sci 1987; 14: 564-569.
18. Berr C, Hauw JJ, Delaere P, Duyckaerts C, Amouyel P. Apolipopro-
tein E allele e4 is linked to increased deposition of the amyloid 
β-peptide (Aβ) in cases with or without Alzheimer's disease. Neu-
rosci Lett 1994; 178: 221-224.
19. Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D,
Fidani L, Goate A, Rossor M, Rocques P, Hardy J, Mullan M. Early
onset Alzheimer’s disease caused by mutations at codon 717 of
the β-amyloid precursor protein gene. Nature 1991; 353: 844-846.
20. Delaere P, Duyckaerts C, He Y, Piette F, Hauw JJ. Subtypes and dif-
ferential laminar distribution of β/A4 deposits in Alzheimer's dis-
ease: Relationship with the intellectual status of 26 cases. Acta
Neuropathol 1991; 81: 328-335.
21. Delaere P, He Y, Fayet G, Duyckaerts C, Hauw J. βA4 deposits are
constant in the brains of the oldest old: An immunocytochemi-
cal study of 20 French Centenarians. Neurobiol Aging 1993; 14: 
191-194.
β-amyloid (Aβ) deposition
137Folia Neuropathologica 2012; 50/2
22. Dickson DW, Ruan D, Crystal H, Mark MH, Davies P, Kress Y, Yen
SH. Hippocampal degeneration differentiates diffuse Lewy body
disease (DLBD) from Alzheimer’s disease: Light and electron micro-
scope immunocytochemistry of CA2-3 neurites specific to DLBD.
Neurology 1991; 41: 1402-1409.
23. Feany MB, Dickson DW. Neurodegenerative disorders with exten-
sive tau pathology: a comparative study and review. Ann Neurol
1986; 40: 139-148.
24. Forstl H. The Lewy body variant of Alzheimer’s disease: clinical,
pathophysiological and conceptual issues. Eur Arch Psych Clin 
Neurol 1999; 249: 64-67.
25. Gearing M, Schneider JA, Robins RS, Hollister RD, Mori H, Games D,
Hyman BT, Mirra SS. Regional variations in the distribution of
Apolipoprotein E and Aβ in Alzheimer’s disease. J Neuropath Exp
Neurol 1995; 54: 833-841.
26. Gibb WR, Luthert PJ, Janota I, Lantos PL. Cortical Lewy body demen-
tia: Clinical features and classification. J Neurol Neurosurg Psy-
chiatr 1989; 52: 185-192.
27. Gibson PH. Form and distribution of senile plaques seen in silver
impregnated sections in the brains of intellectually normal eld-
erly people and people with Alzheimer-type dementia. Neuropathol
Appl Neurobiol 1983; 9: 379-389.
28. Gibson PH. Relationship between numbers of cortical argentophilic
and congophilic senile plaques in the brains of elderly people with
and without senile dementia of the Alzheimer type. Gerontology
1985; 31: 321-324.
29. Gibson PH. Ultrastructural abnormalities in the cerebral neocor-
tex and hippocampus associated with Alzheimer’s disease and
aging. Acta Neuropathol 1987; 73: 86-91.
30. Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome:
sharing of a unique cerebrovascular amyloid fibril protein.
Biochem Biophys Res Commun 1984; 122: 1131-1135.
31. Goate R, Chartier-Harlin M-C, Mullan M, Brown J, Crawford F, Fi -
dani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P,
Rooke K, Roques P, Talbot C, Pericak-Vance, Roses A, Williamson R,
Rossor M, Owen M, Hardy J. Segregation of a missense mutation
in the amyloid precursor protein gene with familial Alzheimer’s
disease. Nature (London) 1991; 349: 704-706.
32. Gomez-Isla T, West HL, Rebeck GW, Harr SD, Growdon JH, Lacas-
cio JJ, Perls TT, Lipsitz LA, Hyman BT. Clinical and pathological cor-
relates of apolipoprotein E e4 in Alzheimer’s disease. Ann Neurol
1996; 39: 62-70.
33. Hansen LA, Salmon D, Galasko D, Masliah E, Katzman R, de Tere-
sa R, Thal L, Pay MM, Hofstetler R, Klauber M, Rice V, Butters VN,
Alford M. The Lewy body variant of Alzheimer’s disease: a clini-
cal and pathological entity. Neurology 1990; 40: 1-8.
34. Harrington CR, Perry RH, Perry EK, Hurt J, McKeith JG, Roth M, Wis-
chik CM. Senile dementia of the Lewy body type and Alzheimer type
are biochemically distinct in terms of paired helical filaments and
hyperphosphorylated tau proteins. Dementia 1994; 5: 215-228.
35. Imhof A, Kovari E, von Gunten A, Gold G, Rivara CB, Herrmann FR,
Hof PR, Bouras C, Glannakopoulos P. Morphological substrates of
cognitive decline in nonagenarians and centenarians: A new par-
adigm? J Neurol Sci 2007; 257: 72-79.
36. Iseki E, Marin W, Kosaka K, Kato M, Yamamoto T, Ueda K. Clini-
copathological multiplicity of dementia with Lewy bodies. Neuro -
pathol 1999; 19: 386-394.
37. Lauterbach EC. The neuropsychiatry of Parkinson’s disease and
related disorders. Psych Clin N Am 2004; 27: 801.
38. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C,
McKeith IG, O’Brien JT. Occipital hypoperfusion on SPECT in demen-
tia with Lewy bodies but not Alzheimer’s disease. Neurol 2001;
56: 643-649.
39. Mann DMA, Tucker CM, Yates PO. Topographic distribution of senile
plaques, neurofibrillary tangles in the brains of non demented per-
sons of different age. Neuropath App Neurobiol 1987; 13: 123-139.
40. Mann DMA, Jones D. Deposition of amyloid A4 protein within the
brains of persons with dementing disorders other than Alzheimer’s
disease and Down’s syndrome. Neurosci Lett 1990; 109: 68-75.
41. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen
LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP,
Edwardosn JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S,
Collerton D, Jansen ENH, Ballard C, de Vos RAI, Wilcock GK, Jellin -
ger KA, Perry RH. Consensus guidelines for the clinical and patho-
 logical diagnosis of dementia with Lewy bodies (DLB): Report of
the consortium on DLB international workshop. Neurology 1996;
47: 1113-1124.
42. Mirra SS, Heyman A, McKeel, D, Sumi SM, Crain BJ, Brownlee LM,
Vogel FS, Hughes JP, van Belle G and Berg L. The consortium to esta -
blish a registry for Alzheimer’s disease (CERAD). Part II Standa -
rdization of the neuropathologic assessment of Alzheimer’s
disease. Neurology 1991; 41: 479-486.
43. Perneczky R, Mosch D, Neumann M, Kretschmar H, Muller U, 
Busch R, Forstl H and Kurz A. The Alzheimer variant of Lewy body
disease: A pathologically confirmed case-control study. Demen
Ger Cog Dis 2005; 20: 89-94.
44. Rosenberg CK, Pericak-Vance MA, Saunders AM, Gilbert JR, Gas -
kell PC and Hulette CM. Lewy body and Alzheimer pathology in
a family with the amyloid-beta precursor protein APP717 gene
mutation. Acta Neuropathol 2000; 100: 145-152.
45. Sherrington R, Rogaev E, Liang Y, Rogaeva E, Levesque G, Ikeda M,
Chi H, Lin C, Li G, Holman K, Tsuda T, Mar L, Foncin J, Bruni A,
Moulese M, Sorbi S, Rainero I, Pinessi L, Nee L, Chumakov I, Pol -
len D, Brookes A, Sauseau P, Polinski R, Wasco R, Dasilva H, Hai -
nes J, Pericak-Vance M, Tanzi R, Roses A, Fraser P, Rommens J, 
St George-Hyslop P. Cloning of a gene bearing missense muta-
 tions in early onset familial Alzheimer’s disease. Nature 1993; 
375: 754-760.
46. Spargo E, Luthert PJ, Anderton BH, Bruce M, Smith D, Lantos
PL. Antibodies raised against different proteins of A4 protein iden-
tify a subset of plaques in Down’s syndrome. Neurosci Lett 1990;
115: 345-350.
47. Szpak GM, Lewandowska E, Lechowicz W, Bertrand E, Wierzba-
Bobrowicz T, Gwiazda E, Pasennik E, Kosno-Kruszewska E, Lip-
czynska-Lozkowska W, Bochynska A, Fiszer U. Lewy body variant
of Alzheimer’s disease and Alzheimer’s disease: a compara ti -
ve immunocytochemical study. Folia Neuropathol 2001; 39: 
63-71.
48. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvasan GS,
Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Ros-
es AD. Binding of human apoliprotein E to synthetic amyloid-β-
peptide: isoform-specific effects and implications for late-onset
Alzheimer's disease. Proc Natl Acad Sci USA 1993; 90: 8098-8102.
Richard A. Armstrong
138 Folia Neuropathologica 2012; 50/2
49. Tierney MC, Fisher RH, Lewis AJ, Zorzitto ML, Snow WG, Reid DW,
Nieuwstraten P. The NINCDS-ADRDA work group criteria for the
clinical diagnosis of probable Alzheimer's disease. Neurology 1988;
38: 359-364.
50. Woodward M, Mackenzie IRA, Hsiung GYR, Jacova C, Feldman H.
Multiple brain pathologies in dementia are common. Eur Ger Med
2010; 1: 259-265.
β-amyloid (Aβ) deposition
139Folia Neuropathologica 2012; 50/2
